-
公开(公告)号：EP2341060B1
公开(公告)日：2019-02-20
申请号：EP10010679.8
申请日：2001-12-12
-
2.发明公开Molecules with extended half-lives, compositions and uses thereof 有权新泽西州的MUSA MITLÄNGERENHALBWERTSZEITEN，ZUSAMMENSETZUNGEN UND DEREN VERWENDUNG
公开(公告)号：EP2354149A1
公开(公告)日：2011-08-10
申请号：EP10010680.6
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-lgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个 或更多的增加FcRn的恒定结构域或片段的亲和力的氨基酸修饰。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断中使用较少量和/或更少频率给药的优点。
-
公开(公告)号：EP2357187A1
公开(公告)日：2011-08-17
申请号：EP10010681.4
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的分子，包括IgG，非IgG免疫球蛋白，蛋白质和非蛋白质剂，所述分子具有一个 或更多增加恒定结构域或片段对FcRn的亲和力的氨基酸修饰。 具有增加的半衰期的此类蛋白质和分子具有在治疗，预防或诊断使用此类分子时需要更少量和/或更少频率给药的优点。
-
4.发明公开Molecules with extended half-lives, compositions and uses thereof 审中-公开MolekülemitlängerenHalbwertszeiten，Zusammensetzungen und deren Verwendung
公开(公告)号：EP2341060A1
公开(公告)日：2011-07-06
申请号：EP10010679.8
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的分子，包括IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂，其具有一个 或更多的增加FcRn的恒定结构域或片段的亲和力的氨基酸修饰。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断中使用较少量和/或更少频率给药的优点。
-
5.发明公开Modulation of antibody specificity by tailoring the affinity to cognate antigens 审中-公开通过调整与无关抗原的亲和力的抗体的特异性的调制
公开(公告)号：EP2422811A2
公开(公告)日：2012-02-29
申请号：EP10173137.0
申请日：2005-10-27
申请人： MedImmune, LLC
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28
CPC分类号： C07K16/2866 , C07K16/005 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/92
摘要： The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of various disorders associated with aberrant expression and/or activity of one or more Eph receptor tyrosine kinase family members and/or one or more Eph receptor ligands, particularly the ephrins. In particular, the invention provides methods for the treatment, management, prevention and/or amelioration of a disorder associated with aberrant expression and/or activity(ies) of one or more Eph receptors and/or one or more ephrins, the method comprising administering to a subject in need thereof an effective amount of one or more Eph/ephrin modulators. The present invention further relates to methods of modulating antibody specificity by tailoring the affinity to cognate antigens.
摘要翻译： 本发明涉及一种设计用于与异常表达和/或一种或多种Eph受体酪氨酸激酶家族成员和/或一个或多个Eph受体配体活性相关的各种疾病的治疗，控制，预防和/或改善的方法和组合物 特别是肝配蛋白。 特别地，本发明提供的一种或多种Eph受体和/或一种或多种肝配蛋白，所述方法包括给予用于治疗与异常表达和/或活性相关的障碍的治疗，控制，预防和/或改善（一个或多个）的方法 在有效量的一种或多种弗/肝配蛋白调节剂在需要其的受试者。 本发明进一步涉及通过调整亲和性的同源抗原的调制抗体特异性的方法。
-
6.发明公开Molecules with reduced half-lives, compositions and uses thereof 审中-公开Molekülemit reduzierter Halbwertzeit，Zusammensetzungen und ihre Verwendung
公开(公告)号：EP2407548A1
公开(公告)日：2012-01-18
申请号：EP11179956.5
申请日：2007-10-16
申请人： MedImmune, LLC
发明人： Dall'Acqua, William , Wu, Herren
IPC分类号： C12P21/08
CPC分类号： C07K16/1027 , C07K2317/52
摘要： The present invention provides polypeptides containing at least the FcRn binding portion of an Fc region of an immunoglobulin molecule and that have altered amino acid sequences relative to wild type immunoglobulin molecules. The polypeptides have decreased in vivo serum half-lives and can be employed in various methods.
摘要翻译： 本发明提供了至少含有免疫球蛋白分子的Fc区的FcRn结合部分并且相对于野生型免疫球蛋白分子具有改变的氨基酸序列的多肽。 多肽具有降低的体内血清半衰期并且可以以各种方法使用。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.023 秒)
